Alternatives to Apixaban for DVT Prophylaxis and Continued Anticoagulation

First-Line DOAC Alternatives

Rivaroxaban, dabigatran, and edoxaban are strongly recommended as alternatives to apixaban for both treatment-phase and extended-phase anticoagulation of VTE, with moderate-certainty evidence supporting their use over VKAs, according to the American College of Chest Physicians 1, 2, 3
The American College of Chest Physicians recommends rivaroxaban, dabigatran, and edoxaban as first-line DOAC alternatives to apixaban for VTE treatment and extended anticoagulation, with moderate-certainty evidence 1, 2, 3

If all DOACs are contraindicated, VKAs, such as warfarin, are suggested for extended-phase anticoagulation, though this is a weaker recommendation with moderate-certainty evidence, as per the American College of Chest Physicians 1, 2
The American College of Chest Physicians suggests VKAs, such as warfarin, as a second-line alternative to DOACs when they are contraindicated, with initial bridging using parenteral anticoagulation and ongoing INR monitoring with a target range of 2-3, according to the National Comprehensive Cancer Network 4

Low-molecular-weight heparin remains preferred over DOACs for cancer-associated VTE, though this is evolving, as stated by the National Comprehensive Cancer Network and the American College of Chest Physicians 3, 4
The National Comprehensive Cancer Network recommends against using apixaban and rivaroxaban in cancer patients due to limited trial data, with a preference for low-molecular-weight heparin, according to the American College of Chest Physicians 4
The American College of Chest Physicians recommends avoiding rivaroxaban in patients with severe renal impairment and using it with caution in those with moderate renal impairment, with consideration of alternative DOACs based on renal clearance profiles 1, 3, 4
The National Comprehensive Cancer Network suggests avoiding apixaban in patients with severe hepatic impairment, as indicated by elevated transaminases or total bilirubin, according to the American College of Chest Physicians 4

The American College of Chest Physicians strongly recommends extended-phase anticoagulation after completing the initial 3-month treatment phase for unprovoked VTE, with reassessment at least annually, according to the American College of Chest Physicians 1, 2
Reduced-dose DOACs, such as rivaroxaban 10 mg daily or apixaban 2.5 mg twice daily, are suggested over full-dose for extended therapy, balancing efficacy with bleeding risk, as recommended by the American College of Chest Physicians 1, 2, 5
Aspirin is much less effective than anticoagulants for preventing recurrent VTE and should not be considered a reasonable alternative when anticoagulation is appropriate, as stated by the American College of Chest Physicians 1, 2

The American College of Chest Physicians recommends initiating rivaroxaban at 15 mg twice daily for 21 days, followed by 20 mg once daily for a minimum 3-month treatment phase, for patients with chronic lower limb DVT, with extended-phase anticoagulation strongly recommended thereafter using either 20 mg or 10 mg once daily indefinitely for unprovoked or persistent risk factor DVT 6
The intensive dosing of rivaroxaban 15 mg orally twice daily for 21 days eliminates the need for initial parenteral anticoagulation, simplifying treatment compared to warfarin-based regimens 6
Transition to rivaroxaban 20 mg once daily after completing the 21-day intensive phase, and continue this dose through completion of the 3-month treatment phase, with all patients reassessed at 3 months to determine the need for extended-phase therapy 6

Extended anticoagulation is strongly recommended for unprovoked DVT and DVT provoked by persistent risk factors, such as active cancer or thrombophilia, using either rivaroxaban 20 mg or 10 mg once daily 6
The decision to extend anticoagulation should be reassessed at least annually and with any significant change in health status, balancing individual bleeding risk against VTE recurrence risk 6

For patients with cancer-associated DVT, apixaban may be preferred over rivaroxaban due to lower GI bleeding risk, although rivaroxaban 15 mg twice daily for 21 days followed by 20 mg daily is an acceptable option 6
Rivaroxaban should be avoided entirely in patients with confirmed antiphospholipid syndrome, especially triple-positive patients, and vitamin K antagonist (warfarin) with target INR 2.5 should be used instead 7, 8